Navigation Links
SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
Date:12/17/2007

DUBLIN, Calif., December 17 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) today announced that investigators have dosed the first patient in a multi-arm Phase 1b clinical trial of MP470, a novel, oral, multi-targeted tyrosine kinase inhibitor (TKI). The trial will evaluate MP470 in combination with several standard of care chemotherapy regimens, including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel, topotecan, and erlotinib. The trial is expected to enroll up to 105 patients at five study centers.

The Phase 1b trial is an open label, dose-escalation study designed to assess the safety and tolerability of MP470 in combination with these standard of care chemotherapy regimens, and to define the dose of MP470 to advance into Phase 2 combination studies. Additionally, the Company will assess pharmacokinetic and biomarker data from the study. The trial is open to chemotherapy nave or treatment experienced patients with a variety of solid tumors irrespective of previous lines of therapy.

"MP470 shows significant preclinical synergy with all of these well established chemotherapy agents. Its preclinical toxicology profile, as well as preliminary safety data from our ongoing Phase 1 trial suggests it will be safe to combine it with these regimens," said Dr. Gregory Berk, Chief Medical Officer of SuperGen. "In preclinical models, MP470 also suppresses Rad51, a protein that plays a key role in the mechanism of resistance to these treatments. We believe this offers the potential for MP470 to improve on the efficacy of these therapies. The multi-arm, Phase 1b design allows us to accelerate the clinical development of MP470 which will expedite the timeline to our Phase 2 program."

About MP470

MP470 is
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
2. Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... , NEW YORK, Dec. 9 MR, CT, PET - we,ve ... these hi-tech imaging scans? Here,s more on what questions you ... hood with a medical scan. , Listen to this report from ... a division of The NewsMarket. Registered journalists can access video, ...
... , , , INDIANAPOLIS, Dec. 9 ... leading provider of managed voice, Internet and data networking solutions ... that Indiana Blood Center has selected the company to provide ... 11 locations located throughout Indiana. Indiana Blood Center will also ...
Cached Medicine Technology:Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services 2
(Date:7/9/2014)... low back pain are not linked to weather conditions ... precipitation. Findings published in Arthritis Care & Research ... (ACR), indicate that the risk of low back pain ... but was not clinically significant. , According to ... back pain at some point in their life, making ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective and ... patients. This is the result of a study led ... for Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. ... in advance of print in the American Journal ... C. diff , has increased to epidemic proportions ...
(Date:7/9/2014)... 2014 There has been a sharp increase in ... Center using MyChart, the online, interactive service that allows ... their healthcare providers, schedule appointments, and renew prescriptions. , ... using MyChart each year increased five-fold, while ... than 10-fold, according to a study by Dr. ...
(Date:7/9/2014)... of Allergy and Infectious Diseases (NIAID), part of ... early-stage clinical trial of CRS3123, an investigational oral ... ( C. difficile ) infection. CRS3123 (previously known ... C. difficile growth while sparing normal intestinal bacteria. ... to 30 healthy men and women ages 18 ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... new health reform in China have been released after ... the most important policies ,The National Essential Drug System,. ... high cost of drugs in China through a government-initiated ... that cover a wide range of diseases and meet ...
... today a partnership with Medical Hair Restoration. , ... ... LLC, an online lead generation company, announced today a partnership with ... property, USHairReplacement.com, we wanted to partner with one of the industry ...
... ScarArt is a specially designed temporary tattoo to fit horizontal tummy tuck ... It is waterproof, smear proof and was designed to last 1-3 days. ... ... TX (PRWEB) May 21, 2009 -- ScarArt, an innovative new company specializing ...
... source of information on multiple sclerosis medications and the financial ... ... 21, 2009 -- NeedyMeds, a national nonprofit, added a new resource page ... The page is a multiple sclerosis-specific source of help for those looking ...
... OAK BROOK, Ill., May 21 The University HealthSystem ... 3-year agreement with Mzinga, Inc. for on-demand learning solutions. ... and became effective on March 1, 2009, positions Mzinga ... UHC member hospitals throughout the United States, building on ...
... be associated with obesity. But a new study published ... that the disorder is widely undiagnosed among obese individuals with ... symptoms, but were never diagnosed. , For those with untreated ... existing research shows that it can also mean an increased ...
Cached Medicine News:Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 2Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 3Health News:The Oro Organization, LLC Partners with Medical Hair Restoration to Launch New Website USHairReplacement.com 2Health News:ScarArt -Creatively Camouflage Abdominal Scars 2Health News:New Source of Information on Multiple Sclerosis Medications 2Health News:University HealthSystem Consortium Selects Mzinga for On-Demand Learning Services 2Health News:University HealthSystem Consortium Selects Mzinga for On-Demand Learning Services 3Health News:More than a bad night's sleep 2
BD Vacutainer Citrate Tubes with 3.2% buffered sodium citrate solution are used for routine coagulation studies....
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
... tubes are available in two ... contains a clotting activator and ... where serum is required for ... tube is suitable where the ...
Inquire...
Medicine Products: